At this stage, we continue the work on modifying the structure of 5-indanesulfonamide derivative 3, which selectively inhibits CA IX [50] and enhances the therapeutic effect of tumor irradiation in vivo [51]. The gene discussed is CA9; the disease is neoplasm.